| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023893 | NODEN PHARMA | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
Mar, 2022
(1 year, 6 months ago) | |
| US8618172 | NODEN PHARMA | Galenical formulations of organic compounds |
Jul, 2028
(4 years from now) | |
Tekturna Hct is owned by Noden Pharma.
Tekturna Hct contains Aliskiren Hemifumarate; Hydrochlorothiazide.
Tekturna Hct has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Tekturna Hct are:
- US9023893
Tekturna Hct was authorised for market use on 18 January, 2008.
Tekturna Hct is available in tablet;oral dosage forms.
The generics of Tekturna Hct are possible to be released after 13 July, 2028.
Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 18 January, 2008
Treatment: NA
Dosage: TABLET;ORAL
TEKTURNA HCT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic